The wider net loss and elevated G&A costs are near-term negatives, but the $50M financing removes near-term cash runway risk through Q2 2027. The stock will likely trade on the upcoming MICVO data readouts in Fall 2026 and Q4 2026, which are the primary catalysts. Monitor for any pre-data announcements or changes to the clinical timeline.
Price Chart
Executive Summary
Pyxis Oncology reported Q2 2026 results with a net loss of $25.3M ($0.40/share), wider than the prior year's $18.4M loss, driven by higher G&A costs. The company completed a ~$50M private placement, extending its cash runway into Q2 2027, and reiterated key MICVO data readouts in Fall 2026 and Q4 2026. The wider loss and lack of revenue are negatives, but the strengthened balance sheet and on-track pipeline milestones provide a counterbalance for a pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Net loss of $25.3M ($0.40/share) for Q2 2026 vs $18.4M ($0.30/share) in Q2 2025.
- Completed private placement with upfront gross proceeds of ~$50M, extending cash runway into Q2 2027.
- Cash and investments were $34.5M as of June 30, 2026, plus $10M received on June 30 from the private placement.
- MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC on track for Fall 2026; combination data with pembrolizumab on track for Q4 2026.
- R&D expenses decreased to $16.1M from $17.1M YoY; G&A expenses increased to $9.9M from $5.4M YoY due to severance and stock-based compensation.
Financial Impact
Net loss widened by $6.9M YoY to $25.3M; cash runway extended into Q2 2027 via $50M private placement.
Risk Factors
- Dilution from the private placement and potential warrant exercises.
- Clinical trial risk — MICVO data may not meet efficacy or safety expectations.
- Cash runway only extends to Q2 2027, requiring additional financing before data maturity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347911 |
| Document: pyxs-20260813.htm | 0001193125-26-347911 |
| Document: 0001193125-26-347911-index-headers.html | 0001193125-26-347911 |
| Document: 0001193125-26-347911-index.html | 0001193125-26-347911 |
| Document: 0001193125-26-347911.txt | 0001193125-26-347911 |
| 8-K Data (Synthetic) | 0001193125-26-347911 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access